The U.S. Food and Drug Administration flagged data integrity, manufacturing, and maintenance lapses at a Dabur India Ltd. plant [1].
These findings are significant because they indicate a failure to meet good manufacturing practices, potentially compromising the safety and quality of products intended for the U.S. market.
The FDA identified issues involving data integrity and maintenance failures at the company's manufacturing facility located in Dadra and Nagar Haveli, India [1], [2]. The regulator said these lapses created a risk of microbiological contamination [2].
The findings follow an inspection conducted by the agency in January 2024 [1]. The regulator said these specific findings on May 29, 2024 [2].
Data integrity is a critical component of pharmaceutical and supplement manufacturing, ensuring that the records used to verify product safety are accurate and unaltered. The FDA's report suggests that the facility violated required good manufacturing practices, which are standards designed to ensure the consistency and purity of medicinal products [1], [2].
While the FDA has not issued a final sanction in the provided reports, such warnings typically require companies to implement corrective and preventive action plans. Failure to resolve these issues can lead to import alerts or the banning of specific facilities from shipping goods to the U.S. [1].
“The FDA identified data-integrity issues, manufacturing/maintenance lapses and a risk of microbiological contamination.”
This regulatory action highlights the ongoing scrutiny of Indian manufacturing facilities by the FDA. For Dabur India, these findings may lead to increased operational costs as they overhaul maintenance protocols and data logging systems to avoid potential import bans on their products entering the U.S. market.
